Patients who took the frequently prescribed diabetes and weight-loss drugs Ozempic and Wegovy faced a greater risk of a ...

Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. HealthDay News — Semaglutide is associated with nonarteritic anterior ...

About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was ...

People who take semaglutide—the active ingredient in Ozempic and Wegovy—may have a higher risk of a rare eye condition called ...

After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data ...

including nonarteritic anterior ischemic optic neuropathy, neuromyelitis optica, inflammatory optic neuropathies (sarcoid, lupus and giant cell arteritis), infectious optic neuropathies (Lyme ...

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION ...

Study suggests Semaglutide a popular antidiabetic drug may be linked to vision loss Learn about the potential risks and ...

Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic ...

What is NAION and how common is it? Nonarteritic anterior ischemic optic neuropathy, or NAION, is a rare condition that afflicts 2 to 10 out of 100,000 people. Like a brain stroke, the condition ...